Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02763384
Previous Study | Return to List | Next Study

BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02763384
Recruitment Status : Recruiting
First Posted : May 5, 2016
Last Update Posted : October 31, 2018
Sponsor:
Collaborator:
The Leukemia and Lymphoma Society
Information provided by (Responsible Party):
Washington University School of Medicine

Brief Summary:

The outcome of patients with relapsed or refractory adult T-acute lymphoblastic leukemia (T-ALL) and the related disease T-lymphoblastic lymphoma (T-LBL) is extremely poor with 30% of the patients responding to first salvage therapy and long-term survival of only 10%. Therefore, novel therapies for patients with relapsed/refractory T-ALL/LBL represent an unmet clinical need.

Recent data provide strong evidence that CXCR4 signaling plays a major role in T-cell leukemia cell maintenance and leukemia initiating activity, and targeting CXCR4 signaling in T-ALL cells reduces tumor growth in an animal model. In this study, the investigators propose that the addition of BL-8040 to nelarabine as a salvage therapy for patients with relapsed/refractory T-ALL/LBL will result in a higher CR rate than nelarabine alone without an increase in toxicity and will allow patients to proceed to a potentially curative allogeneic hematopoietic cell transplant.


Condition or disease Intervention/treatment Phase
T-Acute Lymphoblastic Leukemia Adult T Lymphoblastic Lymphoma Drug: BL-8040 Drug: Nelarabine Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Actual Study Start Date : December 2, 2016
Estimated Primary Completion Date : May 31, 2019
Estimated Study Completion Date : April 30, 2021


Arm Intervention/treatment
Experimental: Arm 1: BL-8040 and Nelarabine
  • Cycle 1: BL-8040 subcutaneous daily from Day 1 to Day 6 and nelarabine intravenously over 2 hours on Days 2, 4, and 6
  • Cycles 2-4: BL-8040 subcutaneous daily from Day 1 to Day 5 and nelarabine intravenously over 2 hours on Days 1, 3, and 5
  • Treatment may be repeated every 21 days for up to 4 cycles
Drug: BL-8040
Drug: Nelarabine
Other Name: Arranon




Primary Outcome Measures :
  1. Safety and tolerability of regimen as measured by frequency and grade of adverse events [ Time Frame: Up to 30 days after completion of treatment (approximately 16 weeks) ]
    The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all adverse event reporting.


Secondary Outcome Measures :
  1. Pharmacodynamic effects of BL-8040 on T-lymphoblasts as measured by inhibition of CXCR4 signaling on lymphoblasts [ Time Frame: Completion of treatment (approximately 12 weeks) ]
    Pharmacodynamic effects of BL-8040 on T-lymphoblasts as measured by inhibition of CXCR4 signaling on lymphoblasts

  2. Pharmacodynamic effects of BL-8040 on T-lymphoblasts as measured by mobilization of lymphoblasts into the peripheral circulation [ Time Frame: Completion of treatment (approximately 12 weeks) ]
    Pharmacodynamic effects of BL-8040 on T-lymphoblasts as measured by mobilization of lymphoblasts into the peripheral circulation

  3. Pharmacodynamic effects of BL-8040 on T-lymphoblasts as measured by induction of apoptosis in lymphoblasts [ Time Frame: Completion of treatment (approximately 12 weeks) ]
    Pharmacodynamic effects of BL-8040 on T-lymphoblasts as measured by induction of apoptosis in lymphoblasts

  4. Pharmacodynamic effects of BL-8040 on T-lymphoblasts as measured by alterations in lymphoblast cell cycle status [ Time Frame: Completion of treatment (approximately 12 weeks) ]
    Pharmacodynamic effects of BL-8040 on T-lymphoblasts as measured by alterations in lymphoblast cell cycle status

  5. Estimate composite complete remission rate (CRc=CR+CRi) [ Time Frame: Completion of treatment (approximately 12 weeks) ]

    Complete remission (CR) = an absolute neutrophil count (segs and bands) > 1,000/mcL, no circulating lymphoblasts, platelets ≥ 100,000/mcL; and < 5% marrow leukemia blast cells with complete disappearance of all measurable disease as confirmed by physical examination, CT scan and/or FDG-PET (Deauville criteria score of 1, 2, or 3)

    -Morphologic complete remission with incomplete blood count recovery (CRi)=Defined as CR with the exception of neutropenia < 1,000/mcL or thrombocytopenia <100,000/mcL


  6. Estimate overall response rate (CR, CRi + PR) [ Time Frame: Completion of treatment (approximately 12 weeks) ]

    Complete remission (CR) = an absolute neutrophil count (segs and bands) > 1,000/mcL, no circulating lymphoblasts, platelets ≥ 100,000/mcL; and < 5% marrow leukemia blast cells with complete disappearance of all measurable disease as confirmed by physical examination, CT scan and/or FDG-PET (Deauville criteria score of 1, 2, or 3)

    • Morphologic complete remission with incomplete blood count recovery (CRi)=Defined as CR with the exception of neutropenia < 1,000/mcL or thrombocytopenia <100,000/mcL
    • Partial remission (PR)=A PR requires all of the CR criteria except that marrow may still contain 5-25% leukemia blast cells. An absolute neutrophil count (segs and bands) ≥ 1000/mcL, no circulating blasts, and platelets > 100,000/mcL are requires as for a CR. For patients with measurable disease, a reduction of 50% or more in the sum of the products of the perpendicular diameters of all measurable lesions compared with pretreatment measurements and with no new or enlarging lesions

  7. Time to response [ Time Frame: Up to 2 years after completion of treatment (approximately 116 weeks) ]
    Time to response

  8. Duration of response [ Time Frame: Up to 2 years after completion of treatment (approximately 116 weeks) ]
    Defined as the interval from the date CR/CRi is documented to the date of recurrence.

  9. Disease-free survival [ Time Frame: Up to 2 years after completion of treatment (approximately 116 weeks) ]
    For patients achieving a complete remission, defined as the interval from the date of first documentation of CR/CRi to the date of recurrence or death due to any cause.

  10. Event-free survival [ Time Frame: Up to 2 years after completion of treatment (approximately 116 weeks) ]
    Defined as the interval from the date of first dose of study drug to date of treatment failure, recurrence, or death due to any cause.

  11. Overall survival [ Time Frame: Up to 2 years after completion of treatment (approximately 116 weeks) ]
    Defined as the date of first dose of study drug to the date of death from any cause.

  12. Estimate rate of patients who proceed to alloHCT after treatment [ Time Frame: Completion of treatment (approximately 12 weeks) ]
    Estimate rate of patients who proceed to alloHCT after treatment

  13. Interaction of pretreatment disease and morphology on clinical outcome [ Time Frame: Up to 2 years after completion of treatment (approximately 116 weeks) ]
    Interaction of pretreatment disease and morphology on clinical outcome

  14. Interaction of pretreatment disease and CXCR4 expression on lymphoblasts on clinical outcome [ Time Frame: Up to 2 years after completion of treatment (approximately 116 weeks) ]
    Interaction of pretreatment disease and CXCR4 expression on lymphoblasts on clinical outcome

  15. Interaction of pretreatment disease and cytogenetics on clinical outcome [ Time Frame: Up to 2 years after completion of treatment (approximately 116 weeks) ]
    Interaction of pretreatment disease and cytogenetics on clinical outcome

  16. Interaction of pretreatment disease and immunophenotype on clinical outcome [ Time Frame: Up to 2 years after completion of treatment (approximately 116 weeks) ]
    Interaction of pretreatment disease and immunophenotype on clinical outcome

  17. Interaction of pretreatment disease and white blood cell count on clinical outcome [ Time Frame: Up to 2 years after completion of treatment (approximately 116 weeks) ]
    Interaction of pretreatment disease and white blood cell count on clinical outcome

  18. Interaction of pretreatment disease and performance status on clinical outcome [ Time Frame: Up to 2 years after completion of treatment (approximately 116 weeks) ]
    Interaction of pretreatment disease and performance status on clinical outcome



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of T-acute lymphoblastic leukemia/ lymphoblastic lymphoma according to WHO criteria which has relapsed or is refractory to chemotherapy.
  • Peripheral blood lymphoblasts ≤ 50,000 mcL. Hydroxyurea and/or leukapheresis is permitted to reduce the peripheral blast count prior to enrollment and treatment.
  • Age ≥ 18 years
  • ECOG performance status ≤ 2.
  • Adequate organ function defined as:

    • Calculated creatinine clearance ≥ 50 ml/min using the Cockroft-Gault formula
    • AST, ALT, total bilirubin ≤ 2 x institutional ULN except for Gilbert's disease or when in the opinion of treating physician elevated levels are due to direct involvement of leukemia (e.g., hepatic infiltration or biliary obstruction due to leukemia), in which case ALT and AST may be elevated up to ≤ 5 x IULN.
  • Women of childbearing potential and men must agree to use adequate contraception with a highly effective method (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Abstinence is acceptable if this is the established and preferred contraception for the subject.
  • Female subjects must have a negative urine or serum pregnancy test within 72 hours prior to start of study treatment if of childbearing potential or be of non-childbearing potential. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. The serum pregnancy test must be negative for the subject to be eligible. Non-childbearing potential is defined as:

    *≥ 45 years of age and has not had menses for > 2 years

    • Amenorrheic for > 2 years without a hysterectomy and oophorectomy and a FSH value in the postmenopausal range upon pretrial (screening) evaluation
    • Post-hysterectomy, oophorectomy, or tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure.
  • Able to understand and willing to sign an IRB-approved written informed consent document.

Exclusion Criteria:

  • Previous treatment with nelarabine for relapsed or refractory disease.
  • Pregnant or nursing.
  • Received any other investigational agent or systemic cytotoxic chemotherapy within the preceding 2 weeks.
  • Active CNS involvement with leukemia
  • Active HIV or hepatitis B or C infection.
  • Any medical condition which, in the opinion of the clinical investigator, would interfere with the evaluation of the patient. Subjects with a clinically significant or unstable medical or surgical condition or any other condition that cannot be well-controlled by the allowed medications permitted in the study protocol that would preclude safe and complete study participation, as determined by medical history, physical examinations, laboratory tests, and according to the investigator's judgment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02763384


Contacts
Layout table for location contacts
Contact: Geoffrey L Uy, M.D. 314-747-8439 guy@wustl.edu

Locations
Layout table for location information
United States, Illinois
The University of Chicago Medical Center Recruiting
Chicago, Illinois, United States, 60637
Contact: Wendy Stock, M.D.    773-834-8982    wstock@medicine.msd.uchicago.edu   
Principal Investigator: Wendy Stock, M.D.         
Sub-Investigator: Andrew Artz, M.D.         
Sub-Investigator: Satyajit Kosuri, M.D.         
Sub-Investigator: Jane Churpek, M.D.         
Sub-Investigator: Richard A Larson, M.D.         
Sub-Investigator: Sonali Smith, M.D.         
Sub-Investigator: Emily Curran, M.D.         
Sub-Investigator: Hongtao Liu, M.D., Ph.D.         
Sub-Investigator: Michael Thirman, M.D.         
Sub-Investigator: Lucy A Godley, M.D., Ph.D.         
United States, Missouri
Washington University School of Medicine Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Geoffrey L Uy, M.D.    314-747-8439    guy@wustl.edu   
Principal Investigator: Geoffrey L Uy, M.D.         
Sub-Investigator: Daniel C Link, M.D.         
Sub-Investigator: Bader Alahmari, M.D.         
United States, Ohio
The Ohio State University Wexner Medical Center, James Cancer Hospital Recruiting
Columbus, Ohio, United States, 43210
Contact: Jonathan Brammer, M.D.    614-366-6963      
Principal Investigator: Jonathan Brammer, M.D.         
Sub-Investigator: Gregory Behbehani, M.D., Ph.D.         
Sub-Investigator: Bhavana Bhatnagar, D.O.         
Sub-Investigator: James Blachly, M.D.         
United States, Texas
The University of Texas MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Tapan Kadia, M.D.    713-792-2121    tkadia@mdanderson.org   
Principal Investigator: Tapan Kadia, M.D.         
Sub-Investigator: Alessandra Ferrajoli, M.D.         
Sub-Investigator: Courtney DiNardo, M.D.         
Sub-Investigator: Elias Jabbour, M.D.         
Sub-Investigator: Farhad Ravandi-Kashani, M.D.         
Sub-Investigator: Gautam Borthakur, M.D.         
Sub-Investigator: Guillerno Garcia-Manero, M.D.         
Sub-Investigator: Hagop Kantarjian, M.D.         
Sub-Investigator: Jan A Burger, M.D., Ph.D.         
Sub-Investigator: Jorge Cortes, M.D.         
Sub-Investigator: Marina Konopleva, M.D., Ph.D.         
Sub-Investigator: Maro Ohanian, D.O.         
Sub-Investigator: Michael Andreeff, M.D., Ph.D.         
Sub-Investigator: Naval Davar, M.D.         
Sub-Investigator: Naveen Pemmaraju, M.D.         
Sub-Investigator: Nitin Jain, M.D.         
Sub-Investigator: Srdan Verstovsek, M.D., Ph.D.         
Sub-Investigator: Steven Kornblau, M.D.         
Sub-Investigator: William Wierda, M.D., Ph.D.         
Sub-Investigator: Yesid Alvarado-Valero, M.D.         
Sub-Investigator: Zeev Estrov, M.D.         
Sub-Investigator: Khanh Nguyen, M.D., FACP         
Sub-Investigator: Etsuko Aoki, M.D.         
Sub-Investigator: Koichi Takahashi, M.D.         
Sub-Investigator: Prithviraj Bose, M.D.         
Sub-Investigator: Philip Thompson, M.B., B.S.         
Sub-Investigator: Kiran Naqvi, M.D.         
Sub-Investigator: Musa Yilmaz, M.D.         
Sub-Investigator: Christopher Benton, M.D.         
Sub-Investigator: Kapil Bhalla, M.D., FACP         
Sponsors and Collaborators
Washington University School of Medicine
The Leukemia and Lymphoma Society
Investigators
Layout table for investigator information
Principal Investigator: Geoffrey L Uy, M.D. Washington University School of Medicine

Additional Information:
Layout table for additonal information
Responsible Party: Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT02763384     History of Changes
Other Study ID Numbers: 201606146
First Posted: May 5, 2016    Key Record Dates
Last Update Posted: October 31, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Lymphoma, Non-Hodgkin
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases